Clinical Trials Logo

Hidradenitis Suppurativa clinical trials

View clinical trials related to Hidradenitis Suppurativa.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 3

NCT ID: NCT04792957 Not yet recruiting - Psoriasis Clinical Trials

JAK-STAT Signaling Pathway in Pyoderma Gangrenosum

Start date: May 1, 2022
Phase:
Study type: Observational

The investigators hypothese that Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma gangrenosum (PG). In this study JAK/STAT signaling pathway will be investigated in the skin biopsies of PG patients

NCT ID: NCT04388163 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

Gentian Violet Treatment for Hidradenitis Suppurativa

Start date: May 2024
Phase: Phase 2
Study type: Interventional

This is a survey study being conducted to describe how subjects with Hidradenitis suppurativa (HS) respond to treatment with gentian violet. The study will rely primarily on qualitative survey responses and quantitative changes in skin appearance.

NCT ID: NCT03910803 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

Treatment of Moderate Hidradenitis Suppurativa

Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

The study will be conducted over 24 weeks on active therapy followed by a four-week observational visit. The total length of the study will be 28 weeks. Study visits will occur at Screening, Baseline (Week 0), Weeks 4, 8, 12, 16, 20, 24 followed by an observational visit. Additionally, all subjects will be contacted by phone 1 week following the Baseline visit to ensure daily pain assessments are being recorded. If any signs or symptoms are reported at the time of the call, an unscheduled study visit will be conducted to assess whether an infection is present. Adverse events will be collected throughout the study.